转移性结直肠癌一线治疗肿瘤大小反应可预测总生存
该回顾性描述性单中心研究纳入65例不可切除转移性结直肠癌患者,按RECIST 1.1一线最佳反应分组,分析长期肿瘤大小演变与生存关系。结果显示一线出现早期肿瘤缩小(ETSfl)者后续治疗反应更好、总生存更长(29.9个月),而一线进展(PDfl)者后续治疗持续难治、总生存更短(17.1个月),差异具统计学意义(p=0.03)。
要点
- 一线化疗出现早期肿瘤缩小者后续治疗反应更好,中位总生存29.9个月。
- 一线进展者后续治疗持续难治,中位总生存17.1个月,肿瘤负荷快速增加。
- 作者强调即使非临床试验,一线治疗开始后8周行首次CT按RECIST再评估对判断长期演变至关重要。
核心结论
- 一线化疗应答的肿瘤对后续治疗线也应答更好,而一线进展的转移性结直肠癌对其他治疗持续难治,这可能解释早期肿瘤缩小与总生存之间的关联。
研究设计与样本
- 回顾性描述性单中心研究,纳入2010至2015年间65例不可切除转移性结直肠癌患者,按RECIST 1.1一线最佳反应分组:进展(PDfl)、稳定且肿瘤大小变化0至+19%(SDfl+)或0至-29%(SDfl-)、部分缓解(PR),PR再分为伴早期肿瘤缩小(ETSfl)与不伴(PRfl);分析肿瘤大小演变及各化疗线最佳肿瘤反应。
关键影像表现/征象
- ETSfl或PRfl的转移性结直肠癌肿瘤负荷倾向于保持在初始值以下:60%的患者死亡时靶病灶总和低于基线。
- 一线SDfl+或PDfl的转移性结直肠癌在后续治疗线中肿瘤负荷快速增加:>80%死亡时靶病灶总和高于基线。
- ETSfl的转移性结直肠癌对后续治疗线反应更好(二线PR率37.5%),而PDfl者对二线和三线PR率均为0%。
诊断标准与关键数值
- 按RECIST 1.1一线最佳反应分组:PDfl为进展,SDfl+为肿瘤大小变化0至+19%,SDfl-为0至-29%,PR为部分缓解,PR再分ETSfl(伴早期肿瘤缩小)与PRfl(不伴)。
- ETSfl组总生存29.9个月(95%CI:12.6-47.1),PDfl组总生存17.1个月(95%CI:1.5-37.5),两组差异p=0.03。
临床应用与阅片要点
- 作者强调即使不在临床试验中,一线治疗开始后8周行首次CT按RECIST再评估对确定转移性结直肠癌长期演变至关重要。
- 一线化疗后肿瘤缩小者后续治疗线反应更好且肿瘤负荷维持较低,可据此解释早期肿瘤缩小与总生存的关联。
- 一线化疗进展的转移性结直肠癌对其他治疗持续难治且肿瘤负荷快速增加,阅片时需注意这一演变模式。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Early tumor shrinkage (ETS) has been reported to be associated with survival of metastatic colorectal cancer (mCRC) patients. Our aim was to analyze long-term tumor-size evolution, according to early mCRC best responses during the first-line therapy, to evaluate first best response-survival links.
METHODS: Sixty-five patients with unresectable mCRCs, treated between 2010 and 2015, were included retrospectively in this descriptive monocenter study and grouped according to their RECIST 1.1 first-line best responses: progressive disease (PDfl), stable disease with tumor-size evolution between 0 and + 19% (SDfl+) or 0 and - 29% (SDfl-), and partial responders (PRs), who were classed PR with ETS (ETSfl) or without (PRfl). Tumor-size evolution and best tumor responses to each chemotherapy line were analyzed.
RESULTS: Tumor loads of ETSfl or PRfl mCRCs tended to remain inferior to their initial values: 60% of patients died with target lesion sums below baseline. For first-line SDfl+ or PDfl mCRCs, rapid tumor load increases continued during successive lines: > 80% died with target lesion sums above baseline. ETSfl mCRCs responded better to subsequent lines (37.5% second-line PR), whereas PDfl mCRCs remained refractory to other therapies (0% second- and third-line PR). Overall survival rates were significantly (p = 0.03) longer for the ETSfl group (29.9 [95% CI: 12.6-47.1] months) and shorter for the PDfl group (17.1 [95% CI: 1.5-37.5] months).
CONCLUSION: Tumors responding to first-line chemotherapy also responded better to subsequent lines, whereas PDfl mCRCs remained refractory, which may explain the better survival associated with ETSfl.
KEY POINTS: • Early shrinking tumors under first-line chemotherapy responded better to subsequent lines, maintaining low tumor loads, potentially explaining the link between early tumor shrinkage and overall survival of metastatic colorectal cancer (mCRC) patients. • mCRCs progressing under first-line chemotherapy remained refractory to other therapies and their tumor loads increased rapidly. • Even outside a clinical trial, an early first CT scan reevaluation with RECIST criteria 8 weeks after starting first-line therapy is crucial to determine long-term mCRC evolution.
引用
- Palmieri LJ, Fihri A, Doat S, et al. Tumor-size responses to first-line is a predictor of overall survival in metastatic colorectal cancer. Eur Radiol. 2019. PMID: 30706121. doi:10.1007/s00330-018-5967-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。